Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615427 | 0.92 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL907240 | 0.86 | CA12 (0.33) | CA12CA1CA9 | |
| SCHEMBL5081258 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL4540250 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9764063 | 0.79 | — | — | |
| SCHEMBL18457667 | 0.79 | CA12 (0.42) | CA12CA1CA9ALDH1A1TSHR | |
| SCHEMBL907451 | 0.78 | ZDHHC20 (0.40) | CA12CA1CA9 | |
| SCHEMBL17689811 | 0.78 | — | — | |
| SCHEMBL26660006 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1614987 | 0.77 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556731-A1 | METHOD FOR THE CHEMICAL MODIFICATION OF METAL OXIDE SURFACES | Justus-Liebig-Universität Gießen (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-8367748-B2 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2013-02-05 | — | — | US | disclosed |
| US-8367748-B2 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2013-02-05 | — | — | US | disclosed |
| EP-2277496-A1 | Dental material containing surface-modified fillers | Ivoclar Vivadent AG (LI) | 2011-01-26 | — | — | EP | disclosed |
| EP-1716836-B1 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2011-01-19 | — | — | EP | disclosed |
| EP-1716836-A1 | Surface-modified fillers | Ivoclar Vivadent AG (LI) | 2006-11-02 | — | — | EP | disclosed |
| US-20060247329-A1 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247329-A1 | Surface-modified fillers | MSR1, HRH4, OR10J3 | CA12 446/4885CA1 738/4885CA9 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.